Mapping the specific cytoprotective interaction of humanin with the pro-apoptotic protein bid.
Choi. Jungyuen J; Zhai. Dayong D; Zhou. Xin X; Satterthwait. Arnold A; Reed. John C JC; Marassi. Francesca M FM
Key Findings
- Humanin binds specifically to the BH3 domain of the pro‑apoptotic protein Bid
- The binding site is on the surface of Bid and includes conserved BH3 residues
- This interaction likely blocks Bid from associating with other Bcl‑2 family proteins, reducing its toxic effect
Practical Outcomes
- While the study doesn’t give a dosage or protocol, it shows that humanin or similar peptides could be engineered to protect cells from stress‑induced death. Biohackers might watch for future supplements or peptide designs that target Bid, but current evidence is only mechanistic.
Summary
Humanin, a tiny naturally occurring peptide, sticks to a specific part of the cell‑death protein Bid, stopping Bid from teaming up with other proteins that trigger apoptosis. This binding could help protect cells from damage, hinting at a way to boost cell survival.
Abstract
Humanin is a short endogenous peptide, which can provide protection from cell death through its association with various receptors, including the pro-apoptotic Bcl-2 family proteins Bid, Bim, and Bax. By using NMR chemical shift mapping experiments, we demonstrate that the interaction between Humanin-derived peptides and Bid is specific, and we localize the binding site to a region on the surface of Bid, which includes residues from the conserved helical BH3 domain of the protein. The BH3 domain mediates the association of Bid with other Bcl-2 family members and is essential for the protein's cytotoxic activity. The data suggest that Humanin exerts its cytoprotective activity by engaging the Bid BH3 domain; this would hinder the association of Bid with other Bcl-2 family proteins, thereby mitigating its toxicity. The identification of a Humanin-specific binding site on the surface of Bid reinforces its importance as a direct modulator of programmed cell death, and suggests a strategy for the design of cytoprotective peptide inhibitors of Bid.
Study Information
pubmed
2007
2007-10-10T00:00:00.000Z
10.1111/j.1747-0285.2007.00576.x
16
53